Technology areas: Biotechnology & Pharmaceuticals • Computing & Software
5 pending office actions • 3 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready
BEIJING DABEINONG BIOTECHNOLOGY CO., LTD. currently has 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are handled by 4 distinct examiners across 3 distinct art units. STCLAIR, ANDREW D is the busiest examiner for this portfolio, with 2 pending office actions currently under his review.
The distribution of 5 pending actions among 4 distinct examiners suggests that examiners are handling a single matter, with the exception of STCLAIR, ANDREW D. The 3 distinct art units involved indicate that the company's biotechnology filings are being reviewed by multiple specialized groups. This spread requires the applicant to manage 4 different examiner relationships simultaneously to resolve the 5 pending office actions. Because STCLAIR, ANDREW D handles 2 of these actions, his specific art unit and examination style represent a concentrated point of contact within the current prosecution cycle. Successfully navigating these 4 distinct examiners across 3 distinct art units will be essential for the active matters.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| Multi-statute (no §101) | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STCLAIR, ANDREW D | 2 | 60.1% | +25.6% |
| ZHENG, LI | 1 | 83.5% | +13.0% |
| DELEO, VICTORIA LYNN | 1 | 41.4% | -44.4% |
| SPEED, DEQUANTARIUS JAVON | 1 | 70.0% | +69.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18062607 | Use of insecticidal protein | STCLAIR, ANDREW D | 512d overdue |
| 18062593 | Use of insecticidal protein | STCLAIR, ANDREW D | 373d overdue |
| 18557777 | USE OF PROTOPORPHYRINOGEN OXIDASE | DELEO, VICTORIA LYNN | 22d |
| 18839890 | Nucleic Acid Sequence for Detecting Glycine Max Plant DBN8205 and Detection Method Therefor | ZHENG, LI | — |
| 17642528 | Mutant Hydroxyphenylpyruvate Dioxygenase Polypeptide, Encoding Gene Thereof and Use Therefor | SPEED, DEQUANTARIUS JAVON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18062607 | Use of insecticidal protein | STCLAIR, ANDREW D | 512d overdue |
| 18062593 | Use of insecticidal protein | STCLAIR, ANDREW D | 373d overdue |
| 18839890 | Nucleic Acid Sequence for Detecting Glycine Max Plant DBN8205 and Detection Method Therefor | ZHENG, LI | — |
| 17642528 | Mutant Hydroxyphenylpyruvate Dioxygenase Polypeptide, Encoding Gene Thereof and Use Therefor | SPEED, DEQUANTARIUS JAVON | — |
| Art Unit | Apps |
|---|---|
| 1662 | 2 |
| 2178 | 2 |
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18839890 | Nucleic Acid Sequence for Detecting Glycine Max Plant DBN8205 and Detection Method Therefor | ZHENG, LI | 1662 | §102§112 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18557777 | USE OF PROTOPORPHYRINOGEN OXIDASE | DELEO, VICTORIA LYNN | 1662 | §103§112 | Final Rejection | 22d | Pending | Oct 27, 2023 |
| 18062593 | Use of insecticidal protein | STCLAIR, ANDREW D | 2178 | §101§103Other | Non-Final OA | 373d overdue | Pending | Dec 07, 2022 |
| 18062607 | Use of insecticidal protein | STCLAIR, ANDREW D | 2178 | §103§112 | Non-Final OA | 512d overdue | Pending | Dec 07, 2022 |
| 17642528 | Mutant Hydroxyphenylpyruvate Dioxygenase Polypeptide, Encoding Gene Thereof and Use Therefor | SPEED, DEQUANTARIUS JAVON | 1663 | §102§103§112 | Final Rejection | — | Pending | Aug 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBEIJING DABEINONG BIOTECHNOLOGY CO., LTD. has 5 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Andrew D Stclair has the most, with 2 of BEIJING DABEINONG BIOTECHNOLOGY CO., LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
